iPS Cell Response to CFTR Modulators: Study of Symdeko in CF Patients Carrying Partial Function Mutations
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Ivacaftor/tezacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- 16 Aug 2019 Status changed from not yet recruiting to recruiting.
- 06 Jun 2019 Planned initiation date changed from 1 Sep 2019 to 1 Aug 2019.
- 12 Apr 2019 Planned initiation date changed from 1 Mar 2019 to 1 Sep 2019.